

Special Issue

Recent Progress in Tuberculosis Vaccine Development

Message from the Guest Editor

Mycobacterium tuberculosis (Mtb), the causative agent of TB, kills more people worldwide than any infectious pathogen. The development of new vaccines capable of preventing Mtb infection, including multidrug-resistant tuberculosis, is an essential component of the strategy to combat the TB epidemic. This recent positive clinical trial data bestow encouraging evidence and represent a critical milestone in global efforts to develop a novel efficacious TB vaccine. This Special Issue, "TB Vaccine Development", will present and update the scientific efforts to replace or potentiate BCG in infants and to develop new TB vaccines for adolescents and adults. We welcome submission of manuscripts that investigate: TB vaccine development, strategies to diversify vaccine platforms, new animal models for TB vaccines, reliable models to predict human protection, immunological correlation of protection, limitations in BCG immunity, and breakthrough findings in the basic immunology of Mtb infection to investigate possible targets of vaccine development. We also encourage submissions of manuscripts that explore novel antigens, adjuvant formulations, and routes of vaccination.

Guest Editor

Dr. Sunhee Lee

Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA

Deadline for manuscript submissions

closed (31 May 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/60458

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).